Treatment options in patients with recurrent ovarian cancer

Angiolo Gadducci, Pierfranco Conte, Claudia Cianci, Simona Negri, Andrea Riccardo Genazzani

Research output: Contribution to journalArticlepeer-review


The majority of patients with advanced ovarian cancer need a second-line treatment for recurrent disease after surgical cytoreduction and first-line chemotherapy. In these patients, treatment planning is mainly dependent on the platinum-free-interval. The patients may be distinguished as platinum-refractory (progression under platinum-based therapy), platinum-resistant (relapse within 6 months), or platinum-sensitive (relapse after 6 months). Patients with platinum-refractory or-resistant disease should be encouraged to enter clinical trials. Alternatively, these patients could receive tamoxifen or a non-platinum single-agent therapy. Since response rate and duration to different single-agents are similar, patient convenience, toxicities from prior treatment, side-effects and costs play a role in the drug selection for salvage chemotherapy. Patients with platinum-sensitive disease should receive carboplatin based or carboplatin-plus paclitaxel-based regimens. Secondary surgical cytoreduction may have a role in highly selected patients with good performance status, with long disease-free interval and without extra-abdominal or liver metastases.

Original languageEnglish
Pages (from-to)3557-3564
Number of pages8
JournalAnticancer Research
Issue number5
Publication statusPublished - 2001


  • Chemotherapy
  • Recurrent ovarian cancer
  • Surgery

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Treatment options in patients with recurrent ovarian cancer'. Together they form a unique fingerprint.

Cite this